"Veeva is a TAM expansion story in our view," Morgan Stanley said. "And the company is executing on that front with early success in both vault and network...We believe some investors are overlooking the opportunity for Veeva to become the leading IT cloud for Life Sciences, beyond just SFA."
"We think the stock now undervalues the long term growth potential of the business, and we are upgrading to "overweight"...we expect increasing positive data around new products, sales to drive shares higher over time for those willing to ride out the noise, while Veeva's growth and margin profile remains among the best in SaaS," the firm added.
Must Read: Warren Buffett's 10 Favorite Stocks
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.